Open Access

PCSK9 inhibitors from bench to real world: a journey to improve CV outcomes in very high-risk patients. - Sponsored by Amgen (Europe) GmbH.

Presentation

4 more presentations in this session

PCSK9 inhibitors: from pre-clinical research to clinical practice.

Speaker: Professor C. Ballantyne (Houston, US)

Thumbnail

Managing patients with PCSK9 inhibitors: navigating the continuum of cardiovascular risk.

Speaker: Professor G. De Ferrari (Pavia, IT)

Thumbnail

PCSK9 inhibitors: what can we learn from 5 years of real-world use? EU data.

Speaker: Professor K. Ray (London, GB)

Thumbnail

PCSK9 inhibitors: what can we learn from 5 years of real-world use? US/Canadian data.

Speaker: Professor S. Goodman (Toronto, CA)

Thumbnail

Access the full session

PCSK9 inhibitors from bench to real world: a journey to improve CV outcomes in very high-risk patients

Speakers: Professor C. Ballantyne, Professor G. De Ferrari, Professor K. Ray, Professor S. Goodman
Thumbnail

About the event

Image

ESC CONGRESS 2020 - The Digital Experience

28 August - 1 September 2020

Sessions Presentations

This platform is supported by

logo Novo Nordisk